We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




BK Virus Biomarkers Determined by Urine Samples

By LabMedica International staff writers
Posted on 11 May 2017
Transplants are lifesaving treatments for patients with end-stage kidney disease but around 25% fail within five years, either because the body begins to reject the new organ, or because a viral infection has taken hold of the kidney.

These two problems require diametrically opposite treatments, but often by the time the cause of the failure is confirmed, it is too late to prevent it. More...
The two problems could be distinguished from each other via the detection of cocktail of proteins shed from the kidney into the patient’s urine. This could form the basis of a urine test to pick up early signs of transplant failure and ensure the correct treatment is given.

Scientists at the Vall d'Hebron University Hospital focused on a virus called BK. The BK virus causes a common infection which most people experience during childhood mainly with no symptoms. Following infection the virus remains in the body, lying dormant in the kidneys and urinary tract. However, when transplant patients are given immune suppressing drugs, the virus can reactivate, infecting and destroying the new kidney. This usually happens within two years of the transplant.

The team conducted a pilot study in four Spanish hospitals involving 30 kidney transplant patients. Ten of the patients had been diagnosed with T cell mediated acute rejection (TCMR), meaning the kidney was being rejected. Another10 had been diagnosed with BK virus nephropathy, meaning the virus was destroying the kidney. The other ten patients had no known problems with their transplanted kidneys (stable graft).

The scientists analyzed urine samples from each patient to find out which proteins were present. The protein analysis was performed using proteomics. Most of the proteins they found are known to come from the human body. However, in those with the viral infection, they were able to detect proteins that are known to come from the BK virus. These were not found in samples from patients with TCMR or with a stable graft. When they looked more closely at the human proteins, they also found that they could use the levels of those proteins to differentiate between patients who had TCMR, BK virus nephropathy or a stable graft.

Ibai Los-Arcos, MD, an emergency medicine physician and co-author of the study said, “If we can confirm these results in a prospective validated cohort of patients, we may be able to develop a urine test to indicate when a kidney transplant is failing, and at a much earlier stage. More importantly, it would be able to differentiate whether it is failing because of the BK virus or because of organ rejection. If that is the case, we will be able to choose the correct treatment to address the problem and hopefully have more successful kidney transplantations.” The study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases, held April 22-25, 2017, in Vienna, Austria.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.